Akanda Corp. AKAN
Medicinal Chemicals and Botanical Products · IPO 2022 · data as of November 13, 2026
Akanda Corp. (AKAN) is a healthcare company listed in the US with a market value of about $3M. In fiscal year 2024 it had revenue of $836664 and net income of -$4M, a net margin of -489.6%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -2134%.
About Akanda
Akanda is listed in the US and classified in medicinal chemicals and botanical products, IPO year 2022. Revenue went from $2062 in 2020 to $836664 in 2024, growth of about 348.8% a year. It was profitable in 0 of the last 6 years in our data.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year revenue growth above 8% a year
Valuation
Growth and quality
Financials, last 6 years
| Fiscal year | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Revenue | $836664 | $423683 | $3M | $41431 | $2062 | — |
| Net income | -$4M | -$32M | -$12M | -$8M | -$2M | -$1M |
| Free cash flow | -$6M | -$2M | -$12M | -$7M | — | — |
| EPS (diluted) | $-1.72 | $-13.51 | $-4.88 | $-3.40 | $-0.96 | $-0.58 |
| Net margin | -489.6% | -7617.7% | -445.0% | -19625.9% | -111600.0% | — |
| ROIC | -74.8% | -8363.1% | -52.3% | -45.0% | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Akanda pay a dividend?
Not currently.
Is Akanda a good stock to buy?
We do not give buy or sell advice. Akanda scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.